Octapharma: Primary Immunodeficiency Diseases trials
The registry lists 11 Primary Immunodeficiency Diseases studies with Octapharma as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 3 8Phase 4 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency DiseasesCompletedNCT03988426Phase 3Results posted
- Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency DiseasesCompletedNCT03939533Phase 3Results posted
- CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIALCompletedNCT03907241Phase 3Results posted
- Study of Octanorm Subcutaneous IG in Patients With PIDCompletedNCT01888484Phase 3Results posted
- High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)CompletedNCT01313507Phase 3Results posted
- A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency DiseasesCompletedNCT01012323Phase 3Results posted
- Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency DiseasesTerminatedNCT00811174Phase 3Results posted
- Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency DiseasesActive, not recruitingNCT04640142Phase 3
- A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid PushCompletedNCT02503293Phase 4
- Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or PumpsCompletedNCT02180763Phase 4
- Octagam 5% Versus Comparator Post Marketing TrialCompletedNCT01859754